Top accelerator startups

14,448 startups · 29 programs

Eugit Therapeutics

Active · Enabling Tissue Targeting of Therapies

7signal of 100 · rising 2
  • went through YCProgram · this site+4
  • team of 2Team size · YC's directory+2.5

A sum of public facts, not a judgement and not investment advice.

Competitors

Adjacent

Also from S22

All of S22

About Eugit Therapeutics

Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years. Cofounded by George Church (Harvard) and funded by Y Combinator (S22).

YC batch
S22 · Summer 2022
Status, per YC
Active
Category
Other
Team size
2
Location
San Francisco, CA, USA; South San Francisco, CA, USA
Checked
7h ago

YC tags: Cell Therapy, Synthetic Biology, Therapeutics, Oncology, Biotechnology

Eugit Therapeutics in S22: 233 companies, 54% AI

Eugit Therapeutics: questions

Which YC batch was Eugit Therapeutics in?

Eugit Therapeutics was in Y Combinator's Summer 2022 batch (S22).

Is Eugit Therapeutics still active?

Y Combinator lists Eugit Therapeutics as active.

Where is Eugit Therapeutics based?

Eugit Therapeutics lists San Francisco, CA, USA; South San Francisco, CA, USA as its location on YC's directory.